Escape from highly effective public CD8+ T-cell clonotypes by HIV
Identifieur interne : 004601 ( PascalFrancis/Curation ); précédent : 004600; suivant : 004602Escape from highly effective public CD8+ T-cell clonotypes by HIV
Auteurs : Maria Candela Iglesias [France] ; Jorge R. Almeida [France, États-Unis] ; Solène Fastenackels [France] ; David J. Van Bockel [Australie] ; Masao Hashimoto [Japon] ; Vanessa Venturi [Australie] ; Emma Gostick [Royaume-Uni] ; Alejandra Urrutia [France] ; Linda Wooldridge [Royaume-Uni] ; Mathew Clement [Royaume-Uni] ; Stephanie Gras [Australie] ; Pascal G. Wilmann [Australie] ; Brigitte Autran [France] ; Arnaud Moris [France] ; Jamie Rossjohn [Australie] ; Miles P. Davenport [Australie] ; Masafumi Takiguchi [Japon] ; Christian Brander [Espagne] ; Daniel C. Douek [États-Unis] ; Anthony D. Kelleher [Australie] ; David A. Price [États-Unis, Royaume-Uni] ; Victor Appay [France]Source :
- Blood [ 0006-4971 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Mapping the precise determinants of T-cell efficacy against viruses in humans is a public health priority with crucial implications for vaccine design. To inform this effort, we performed a comprehensive analysis of the effective CD8+ T-cell clonotypes that constitute responses specific for the HIV p24 Gag-derived KK10 epitope (KRWIILGLNK; residues 263-272) restricted by HLA-B*2705, which are known to confer superior control of viral replication in HIV-infected individuals. Particular KK10-specific CD8+ T-cell clonotypes, characterized by TRBV4-3/TRBJ1-3 gene rearrangements, were found to be preferentially selected in vivo and shared between individuals. These "public" clonotypes exhibit high levels of TCR avidity and Ag sensitivity, which impart functional advantages and enable effective suppression of HIV replication. The early L268M mutation at position 6 of the KK10 epitope enables the virus to avoid recognition by these highly effective CD8+ T-cell clonotypes. However, alternative clonotypes with variant reactivity provide flexibility within the overall KK10-specific response. These findings provide refined mechanistic insights into the workings of an effective CD8+ T-cell response against HIV.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001954
Links to Exploration step
Pascal:11-0412237Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Escape from highly effective public CD8<sup>+</sup> T-cell clonotypes by HIV</title><author><name sortKey="Candela Iglesias, Maria" sort="Candela Iglesias, Maria" uniqKey="Candela Iglesias M" first="Maria" last="Candela Iglesias">Maria Candela Iglesias</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Almeida, Jorge R" sort="Almeida, Jorge R" uniqKey="Almeida J" first="Jorge R." last="Almeida">Jorge R. Almeida</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>19 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Fastenackels, Solene" sort="Fastenackels, Solene" uniqKey="Fastenackels S" first="Solène" last="Fastenackels">Solène Fastenackels</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Van Bockel, David J" sort="Van Bockel, David J" uniqKey="Van Bockel D" first="David J." last="Van Bockel">David J. Van Bockel</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>St Vincent's Centre for Applied Medical Research and the Kirby Institute, University of New South Wales</s1><s2>Darlinghurst</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Hashimoto, Masao" sort="Hashimoto, Masao" uniqKey="Hashimoto M" first="Masao" last="Hashimoto">Masao Hashimoto</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Viral Immunology, Center for AIDS Research, Kumamoto University</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>5 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>Japon</country></affiliation></author><author><name sortKey="Venturi, Vanessa" sort="Venturi, Vanessa" uniqKey="Venturi V" first="Vanessa" last="Venturi">Vanessa Venturi</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Computational Biology Group, Centre for Vascular Research, University of New South Wales</s1><s2>Kensington</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Gostick, Emma" sort="Gostick, Emma" uniqKey="Gostick E" first="Emma" last="Gostick">Emma Gostick</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Urrutia, Alejandra" sort="Urrutia, Alejandra" uniqKey="Urrutia A" first="Alejandra" last="Urrutia">Alejandra Urrutia</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Wooldridge, Linda" sort="Wooldridge, Linda" uniqKey="Wooldridge L" first="Linda" last="Wooldridge">Linda Wooldridge</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Clement, Mathew" sort="Clement, Mathew" uniqKey="Clement M" first="Mathew" last="Clement">Mathew Clement</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Gras, Stephanie" sort="Gras, Stephanie" uniqKey="Gras S" first="Stephanie" last="Gras">Stephanie Gras</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Wilmann, Pascal G" sort="Wilmann, Pascal G" uniqKey="Wilmann P" first="Pascal G." last="Wilmann">Pascal G. Wilmann</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Autran, Brigitte" sort="Autran, Brigitte" uniqKey="Autran B" first="Brigitte" last="Autran">Brigitte Autran</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire d'Immunologie Cellulaire et Tssulaire</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Moris, Arnaud" sort="Moris, Arnaud" uniqKey="Moris A" first="Arnaud" last="Moris">Arnaud Moris</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Rossjohn, Jamie" sort="Rossjohn, Jamie" uniqKey="Rossjohn J" first="Jamie" last="Rossjohn">Jamie Rossjohn</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Davenport, Miles P" sort="Davenport, Miles P" uniqKey="Davenport M" first="Miles P." last="Davenport">Miles P. Davenport</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Complex Systems in Biology Group, Centre for Vascular Research, University of New South Wales</s1><s2>Kensington</s2><s3>AUS</s3><sZ>16 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Takiguchi, Masafumi" sort="Takiguchi, Masafumi" uniqKey="Takiguchi M" first="Masafumi" last="Takiguchi">Masafumi Takiguchi</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Viral Immunology, Center for AIDS Research, Kumamoto University</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>5 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>Japon</country></affiliation></author><author><name sortKey="Brander, Christian" sort="Brander, Christian" uniqKey="Brander C" first="Christian" last="Brander">Christian Brander</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>AIDS Research Institute IrsiCaixa-HIVACAT, Hospital Universitari Germans Trias i Pujol Ctra del Canyet</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>18 aut.</sZ></inist:fA14><country>Espagne</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Institució Catalana de Recerca i Estudis Avançats (ICREA)</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>18 aut.</sZ></inist:fA14><country>Espagne</country></affiliation></author><author><name sortKey="Douek, Daniel C" sort="Douek, Daniel C" uniqKey="Douek D" first="Daniel C." last="Douek">Daniel C. Douek</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>19 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Kelleher, Anthony D" sort="Kelleher, Anthony D" uniqKey="Kelleher A" first="Anthony D." last="Kelleher">Anthony D. Kelleher</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>St Vincent's Centre for Applied Medical Research and the Kirby Institute, University of New South Wales</s1><s2>Darlinghurst</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Price, David A" sort="Price, David A" uniqKey="Price D" first="David A." last="Price">David A. Price</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>19 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Appay, Victor" sort="Appay, Victor" uniqKey="Appay V" first="Victor" last="Appay">Victor Appay</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire d'Immunologie Cellulaire et Tssulaire</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0412237</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0412237 INIST</idno><idno type="RBID">Pascal:11-0412237</idno><idno type="wicri:Area/PascalFrancis/Corpus">001954</idno><idno type="wicri:Area/PascalFrancis/Curation">004601</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Escape from highly effective public CD8<sup>+</sup> T-cell clonotypes by HIV</title><author><name sortKey="Candela Iglesias, Maria" sort="Candela Iglesias, Maria" uniqKey="Candela Iglesias M" first="Maria" last="Candela Iglesias">Maria Candela Iglesias</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Almeida, Jorge R" sort="Almeida, Jorge R" uniqKey="Almeida J" first="Jorge R." last="Almeida">Jorge R. Almeida</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>19 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Fastenackels, Solene" sort="Fastenackels, Solene" uniqKey="Fastenackels S" first="Solène" last="Fastenackels">Solène Fastenackels</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Van Bockel, David J" sort="Van Bockel, David J" uniqKey="Van Bockel D" first="David J." last="Van Bockel">David J. Van Bockel</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>St Vincent's Centre for Applied Medical Research and the Kirby Institute, University of New South Wales</s1><s2>Darlinghurst</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Hashimoto, Masao" sort="Hashimoto, Masao" uniqKey="Hashimoto M" first="Masao" last="Hashimoto">Masao Hashimoto</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Viral Immunology, Center for AIDS Research, Kumamoto University</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>5 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>Japon</country></affiliation></author><author><name sortKey="Venturi, Vanessa" sort="Venturi, Vanessa" uniqKey="Venturi V" first="Vanessa" last="Venturi">Vanessa Venturi</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Computational Biology Group, Centre for Vascular Research, University of New South Wales</s1><s2>Kensington</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Gostick, Emma" sort="Gostick, Emma" uniqKey="Gostick E" first="Emma" last="Gostick">Emma Gostick</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Urrutia, Alejandra" sort="Urrutia, Alejandra" uniqKey="Urrutia A" first="Alejandra" last="Urrutia">Alejandra Urrutia</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Wooldridge, Linda" sort="Wooldridge, Linda" uniqKey="Wooldridge L" first="Linda" last="Wooldridge">Linda Wooldridge</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Clement, Mathew" sort="Clement, Mathew" uniqKey="Clement M" first="Mathew" last="Clement">Mathew Clement</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Gras, Stephanie" sort="Gras, Stephanie" uniqKey="Gras S" first="Stephanie" last="Gras">Stephanie Gras</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Wilmann, Pascal G" sort="Wilmann, Pascal G" uniqKey="Wilmann P" first="Pascal G." last="Wilmann">Pascal G. Wilmann</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Autran, Brigitte" sort="Autran, Brigitte" uniqKey="Autran B" first="Brigitte" last="Autran">Brigitte Autran</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire d'Immunologie Cellulaire et Tssulaire</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Moris, Arnaud" sort="Moris, Arnaud" uniqKey="Moris A" first="Arnaud" last="Moris">Arnaud Moris</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Rossjohn, Jamie" sort="Rossjohn, Jamie" uniqKey="Rossjohn J" first="Jamie" last="Rossjohn">Jamie Rossjohn</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Davenport, Miles P" sort="Davenport, Miles P" uniqKey="Davenport M" first="Miles P." last="Davenport">Miles P. Davenport</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Complex Systems in Biology Group, Centre for Vascular Research, University of New South Wales</s1><s2>Kensington</s2><s3>AUS</s3><sZ>16 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Takiguchi, Masafumi" sort="Takiguchi, Masafumi" uniqKey="Takiguchi M" first="Masafumi" last="Takiguchi">Masafumi Takiguchi</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Viral Immunology, Center for AIDS Research, Kumamoto University</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>5 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>Japon</country></affiliation></author><author><name sortKey="Brander, Christian" sort="Brander, Christian" uniqKey="Brander C" first="Christian" last="Brander">Christian Brander</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>AIDS Research Institute IrsiCaixa-HIVACAT, Hospital Universitari Germans Trias i Pujol Ctra del Canyet</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>18 aut.</sZ></inist:fA14><country>Espagne</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Institució Catalana de Recerca i Estudis Avançats (ICREA)</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>18 aut.</sZ></inist:fA14><country>Espagne</country></affiliation></author><author><name sortKey="Douek, Daniel C" sort="Douek, Daniel C" uniqKey="Douek D" first="Daniel C." last="Douek">Daniel C. Douek</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>19 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Kelleher, Anthony D" sort="Kelleher, Anthony D" uniqKey="Kelleher A" first="Anthony D." last="Kelleher">Anthony D. Kelleher</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>St Vincent's Centre for Applied Medical Research and the Kirby Institute, University of New South Wales</s1><s2>Darlinghurst</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>20 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Price, David A" sort="Price, David A" uniqKey="Price D" first="David A." last="Price">David A. Price</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>19 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Appay, Victor" sort="Appay, Victor" uniqKey="Appay V" first="Victor" last="Appay">Victor Appay</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire d'Immunologie Cellulaire et Tssulaire</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ><sZ>22 aut.</sZ></inist:fA14><country>France</country></affiliation></author></analytic><series><title level="j" type="main">Blood</title><title level="j" type="abbreviated">Blood</title><idno type="ISSN">0006-4971</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Blood</title><title level="j" type="abbreviated">Blood</title><idno type="ISSN">0006-4971</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>CD8 T lymphocyte</term><term>Efficiency</term><term>Hematology</term><term>Human immunodeficiency virus</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>SIDA</term><term>Efficacité</term><term>Lymphocyte T CD8</term><term>Virus immunodéficience humaine</term><term>Hématologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mapping the precise determinants of T-cell efficacy against viruses in humans is a public health priority with crucial implications for vaccine design. To inform this effort, we performed a comprehensive analysis of the effective CD8<sup>+</sup> T-cell clonotypes that constitute responses specific for the HIV p24 Gag-derived KK10 epitope (KRWIILGLNK; residues 263-272) restricted by HLA-B<sup>*</sup>2705, which are known to confer superior control of viral replication in HIV-infected individuals. Particular KK10-specific CD8<sup>+</sup> T-cell clonotypes, characterized by TRBV4-3/TRBJ1-3 gene rearrangements, were found to be preferentially selected in vivo and shared between individuals. These "public" clonotypes exhibit high levels of TCR avidity and Ag sensitivity, which impart functional advantages and enable effective suppression of HIV replication. The early L<sub>268</sub>M mutation at position 6 of the KK10 epitope enables the virus to avoid recognition by these highly effective CD8<sup>+</sup> T-cell clonotypes. However, alternative clonotypes with variant reactivity provide flexibility within the overall KK10-specific response. These findings provide refined mechanistic insights into the workings of an effective CD8<sup>+</sup> T-cell response against HIV.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-4971</s0></fA01><fA03 i2="1"><s0>Blood</s0></fA03><fA05><s2>118</s2></fA05><fA06><s2>8</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Escape from highly effective public CD8<sup>+</sup> T-cell clonotypes by HIV</s1></fA08><fA11 i1="01" i2="1"><s1>CANDELA IGLESIAS (Maria)</s1></fA11><fA11 i1="02" i2="1"><s1>ALMEIDA (Jorge R.)</s1></fA11><fA11 i1="03" i2="1"><s1>FASTENACKELS (Solène)</s1></fA11><fA11 i1="04" i2="1"><s1>VAN BOCKEL (David J.)</s1></fA11><fA11 i1="05" i2="1"><s1>HASHIMOTO (Masao)</s1></fA11><fA11 i1="06" i2="1"><s1>VENTURI (Vanessa)</s1></fA11><fA11 i1="07" i2="1"><s1>GOSTICK (Emma)</s1></fA11><fA11 i1="08" i2="1"><s1>URRUTIA (Alejandra)</s1></fA11><fA11 i1="09" i2="1"><s1>WOOLDRIDGE (Linda)</s1></fA11><fA11 i1="10" i2="1"><s1>CLEMENT (Mathew)</s1></fA11><fA11 i1="11" i2="1"><s1>GRAS (Stephanie)</s1></fA11><fA11 i1="12" i2="1"><s1>WILMANN (Pascal G.)</s1></fA11><fA11 i1="13" i2="1"><s1>AUTRAN (Brigitte)</s1></fA11><fA11 i1="14" i2="1"><s1>MORIS (Arnaud)</s1></fA11><fA11 i1="15" i2="1"><s1>ROSSJOHN (Jamie)</s1></fA11><fA11 i1="16" i2="1"><s1>DAVENPORT (Miles P.)</s1></fA11><fA11 i1="17" i2="1"><s1>TAKIGUCHI (Masafumi)</s1></fA11><fA11 i1="18" i2="1"><s1>BRANDER (Christian)</s1></fA11><fA11 i1="19" i2="1"><s1>DOUEK (Daniel C.)</s1></fA11><fA11 i1="20" i2="1"><s1>KELLEHER (Anthony D.)</s1></fA11><fA11 i1="21" i2="1"><s1>PRICE (David A.)</s1></fA11><fA11 i1="22" i2="1"><s1>APPAY (Victor)</s1></fA11><fA14 i1="01"><s1>Inserm UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie-Paris 6, Hôpital Pitié-Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>8 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>22 aut.</sZ></fA14><fA14 i1="02"><s1>Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>19 aut.</sZ><sZ>21 aut.</sZ></fA14><fA14 i1="03"><s1>St Vincent's Centre for Applied Medical Research and the Kirby Institute, University of New South Wales</s1><s2>Darlinghurst</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>20 aut.</sZ></fA14><fA14 i1="04"><s1>Division of Viral Immunology, Center for AIDS Research, Kumamoto University</s1><s2>Kumamoto</s2><s3>JPN</s3><sZ>5 aut.</sZ><sZ>17 aut.</sZ></fA14><fA14 i1="05"><s1>Computational Biology Group, Centre for Vascular Research, University of New South Wales</s1><s2>Kensington</s2><s3>AUS</s3><sZ>6 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>21 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University</s1><s2>Victoria</s2><s3>AUS</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>15 aut.</sZ></fA14><fA14 i1="08"><s1>AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire d'Immunologie Cellulaire et Tssulaire</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ><sZ>22 aut.</sZ></fA14><fA14 i1="09"><s1>Complex Systems in Biology Group, Centre for Vascular Research, University of New South Wales</s1><s2>Kensington</s2><s3>AUS</s3><sZ>16 aut.</sZ></fA14><fA14 i1="10"><s1>AIDS Research Institute IrsiCaixa-HIVACAT, Hospital Universitari Germans Trias i Pujol Ctra del Canyet</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>18 aut.</sZ></fA14><fA14 i1="11"><s1>Institució Catalana de Recerca i Estudis Avançats (ICREA)</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>18 aut.</sZ></fA14><fA20><s1>2138-2149</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>3178</s2><s5>354000508970090160</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>50 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0412237</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Blood</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Mapping the precise determinants of T-cell efficacy against viruses in humans is a public health priority with crucial implications for vaccine design. To inform this effort, we performed a comprehensive analysis of the effective CD8<sup>+</sup> T-cell clonotypes that constitute responses specific for the HIV p24 Gag-derived KK10 epitope (KRWIILGLNK; residues 263-272) restricted by HLA-B<sup>*</sup>2705, which are known to confer superior control of viral replication in HIV-infected individuals. Particular KK10-specific CD8<sup>+</sup> T-cell clonotypes, characterized by TRBV4-3/TRBJ1-3 gene rearrangements, were found to be preferentially selected in vivo and shared between individuals. These "public" clonotypes exhibit high levels of TCR avidity and Ag sensitivity, which impart functional advantages and enable effective suppression of HIV replication. The early L<sub>268</sub>M mutation at position 6 of the KK10 epitope enables the virus to avoid recognition by these highly effective CD8<sup>+</sup> T-cell clonotypes. However, alternative clonotypes with variant reactivity provide flexibility within the overall KK10-specific response. These findings provide refined mechanistic insights into the workings of an effective CD8<sup>+</sup> T-cell response against HIV.</s0></fC01><fC02 i1="01" i2="X"><s0>002B19</s0></fC02><fC02 i1="02" i2="X"><s0>002B05C02D</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>SIDA</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>AIDS</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>SIDA</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Efficacité</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Efficiency</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Eficacia</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Lymphocyte T CD8</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>CD8 T lymphocyte</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Linfocito T CD8</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Hématologie</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Hematology</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Hematología</s0><s5>06</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Immunodéficit</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Immune deficiency</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Inmunodeficiencia</s0><s5>37</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Immunopathologie</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Immunopathology</s0><s5>39</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Inmunopatología</s0><s5>39</s5></fC07><fN21><s1>283</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004601 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 004601 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:11-0412237
|texte= Escape from highly effective public CD8+ T-cell clonotypes by HIV
}}
| This area was generated with Dilib version V0.6.33. |  |